Habitrol Nicotine Patch Three-Year Exclusivity Sought By Novartis
This article was originally published in The Tan Sheet
Executive Summary
A shortened duration of use and a new, essential clinical investigation supporting OTC use of the Habitrol transdermal nicotine patch merits the granting of three years of marketing exclusivity, Novartis Consumer Health maintains.
You may also be interested in...
Habitrol
CHPA urges FDA to grant marketing exclusivity to Novartis Consumer Health for transdermal nicotine patch. In comments submitted to agency Dec. 7, CHPA says "it is vital for FDA to maintain a regulatory environment conducive to the appropriate switch of drugs from prescription to OTC use." Trade group reiterates Novartis' claim that shortened duration of use and new, essential clinical investigation entitles company to three-year marketing exclusivity (1"The Tan Sheet" Nov. 6, p. 11). FDA is reviewing its initial exclusivity denial
Habitrol
CHPA urges FDA to grant marketing exclusivity to Novartis Consumer Health for transdermal nicotine patch. In comments submitted to agency Dec. 7, CHPA says "it is vital for FDA to maintain a regulatory environment conducive to the appropriate switch of drugs from prescription to OTC use." Trade group reiterates Novartis' claim that shortened duration of use and new, essential clinical investigation entitles company to three-year marketing exclusivity (1"The Tan Sheet" Nov. 6, p. 11). FDA is reviewing its initial exclusivity denial
Habitrol
CHPA urges FDA to grant marketing exclusivity to Novartis Consumer Health for transdermal nicotine patch. In comments submitted to agency Dec. 7, CHPA says "it is vital for FDA to maintain a regulatory environment conducive to the appropriate switch of drugs from prescription to OTC use." Trade group reiterates Novartis' claim that shortened duration of use and new, essential clinical investigation entitles company to three-year marketing exclusivity (1"The Tan Sheet" Nov. 6, p. 11). FDA is reviewing its initial exclusivity denial